Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 2203-2209

  Bu, Qiang ^a   Fang, Yue ^b   Cao, Yuan ^b   Chen, Qiaoyun ^b   Liu, Yangchen ^c  

^a Department of Urology Danyang People's Hospital   (China)

^b JIANGSU UNIVERSITY   (China)

^c TAIXING PEOPLE'S HOSPITAL   (China)

Author keywords

Bladder cancer; Cyclooxygenase 2; miR 101

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; LIPOCORTIN 5; LUCIFERASE; MICRORNA 101; PROPIDIUM IODIDE; SMALL INTERFERING RNA; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MIRN101 MICRORNA, HUMAN; PTGS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CELL SURVIVAL; CELL VIABILITY; CLINICAL EVALUATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; MTT ASSAY; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SEQUENCE ALIGNMENT; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; CYCLOOXYGENASE 2; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEQUENCE ALIGNMENT; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84920270011     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2455     Document Type: Article

References (35)

1. Bo J, Yang G, Huo K, et al: microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J 278: 786-792, 2011.
2. Donat SM: Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J Natl Compr Canc Netw 7: 40-47, 2009.
3. Kakizoe T, Mucci LA, Albertsen PC and Droller MJ: Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urol Nephrol Suppl: 191-212, 2008.
4. Noguchi S, Mori T, Hoshino Y, et al: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 307: 211-220, 2011.
5. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990. (Pubitemid 20218552)
6. Cho HJ, Kim JK, Kim KD, et al: Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237: 56-66, 2006.
7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Kim VN and Nam JW: Genomics of microRNA. Trends Genet 22: 165-173, 2006. (Pubitemid 43290020)
9. Shyu AB, Wilkinson MF and van Hoof A: Messenger RNA regulation: to translate or to degrade. EMBO J 27: 471-481, 2008. (Pubitemid 351225677)
10. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005. (Pubitemid 41161233)
11. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
12. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
13. Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
14. Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 5: 40, 2012.
15. Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
16. Hasegawa K, Ishikawa K, Kawai S, et al: Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor. Oncol Rep 30: 2937-2944, 2013.
17. Wu XL, Cheng B, Li PY, et al: MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol 19: 7758-7765, 2013.
18. He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212, 2012.
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
20. Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 123: 372-379, 2008. (Pubitemid 351842022)
21. Srivastava SK, Tetsuka T, Daphna-Iken D and Morrison AR: IL-1 beta stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 267: F504-F508, 1994.
22. Xiang KM and Li XR: MiR-133b acts as a tumor suppressor and negatively regulates TBPL1 in colorectal cancer cells. Asian Pac J Cancer Prev 15: 3767-3772, 2014.
23. Xu T, Zhou Q, Zhou J, et al: Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci 102: 959-966, 2011.
24. Kang JH, Song KH, Jeong KC, et al: Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 11: 334, 2011.
25. Akutsu Y, Hanari N, Yusup G, et al: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18: 2946-2951, 2011.
26. Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90: 113-117, 2002.
27. Friedman JM, Liang G, Liu CC, et al: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69: 2623-2629, 2009.
28. Strillacci A, Griffoni C, Sansone P, et al: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315: 1439-1447, 2009.
29. Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
30. Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6: 671-678, 2011.
31. Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46: 2295-2303, 2010.
32. Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81: 1524-1529, 2011.
33. Xu Y, An Y, Wang Y et al: miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 29: 2019-2024, 2013.
34. Hwang MK, Kang NJ, Heo YS, Lee KW and Lee HJ: Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha. Biochem Pharmacol 77: 1213-1222, 2009.
35. Duffy CP, Elliott CJ, O'Connor RA, et al: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34: 1250-1259, 1998. (Pubitemid 28342118)